KWA
MLYS icon

Kingswood Wealth Advisors’s Mineralys Therapeutics MLYS Stock Holding History

Kingswood Wealth Advisors’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-9,600
Closed -$260K – 1032
2026
Q1 		$260K Buy
9,600
+2,526
+36% +$74.1K 0.01% 773
2025
Q4 		$257K Sell
7,074
-9,069
-56% -$364K 0.01% 733
2025
Q3 		$612K Buy
+16,143
New +$349K 0.04% 432

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Kingswood Wealth Advisors's MLYS Position: Q2 2026 in Review

Kingswood Wealth Advisors sold out of Mineralys Therapeutics (MLYS) in Q2 2026, closing a stake of 9,600 shares — an estimated $260K sold.

Kingswood Wealth Advisors first reported a position in MLYS in Q3 2025 and held it in 3 quarters. The position peaked at $612K in Q3 2025. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Kingswood Wealth Advisors reported no remaining Mineralys Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Kingswood Wealth Advisors sold 9,600 Mineralys Therapeutics shares in Q2 2026, an estimated $260K.
  • Kingswood Wealth Advisors first reported a position in Mineralys Therapeutics in Q3 2025 and held it in 3 quarters.
  • Kingswood Wealth Advisors's Mineralys Therapeutics position peaked at $612K in Q3 2025.
  • 224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Kingswood Wealth Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.